Prof. Dr. Ayşe Mavi

  • İlgi Alanları: Meme Kanseri, PET/CT, Samaryum Ttedavisi, Radyomikroküre Tedavisi, Tiroid Hastalıkları, Nükleer Tıp Uygulamaları

Eğitim ve Uzmanlık
1985 - 1991 - Hacettepe Tıp Fakültesi - Lisans
1999 - 2002 - Dokuz Eylül Üniversitesi - Tıpta Uzmanlık (Arş. Görevlisi) Tıp Fakültesi

Deneyim
Öğr. Gör. Tıp Fakültesi Dokuz Eylül Üniversitesi: 2002 -2003
Research Fellowship Hospital of the University of Pennsylvania, Department of Radiology, Division of Nuclear Medicine:  2003 - 2006
Yrd. Doç. Dr. Tıp Fakültesi Yeditepe Üniversitesi:  2006 – 2008
Doçent. Dr. Tıp Fakültesi Yeditepe Üniversitesi:  2008 – 2010
Doçent. Dr. Lifemed Tıp merkezi:  2010 – 2011
Doçent. Dr. Maltepe Üniversitesi İngilizce Tıp fakültesi Nükleer Tıp dersleri :  2015-2016
Doçent. Dr. Maltepe Üniversitesi İngilizce Tıp ve Türkçe tıp Fakültelerinde Nükleer Tıp dersleri: 2016 - 2017 
Doçent. Dr. Maya Nükleer Tıp Merkezi Mesul Müdür: 2012 – 2018
Prof. Nişantaşı Üniversitesi, 2018 halen devam ediyor.
 

7. 1. Uluslararası hakemli dergilerde yayımlanan makaleler (36)

  • 20 si Science Citation Indexde taranan ve Tübitak’ın (A) listesinde yer alan dergilerde 
  •  6’sı   Science Citation Indexde taranan ve Tübitak’ın (B) listesinde yer alan
  •  10u    Science Citation Indexde taranan diğer hakemli uluslararası dergilerde 

7.1. 1. Değirmenci B, Mavi A, Ozkal S, Itil O, Havitcioglu H, Ozaksoy D, Yilmaz M, Kaya GC. Tl-201 Uptake in Bone and Soft Tissue Involvement of Sarcoidosis. Clin Nucl Med 2001; 26(6):499-501.  

7.1. 2. Mavi A, Değirmenci B, Bekis R, Durak H. Intra-Abdominal Splenosis Mimicking Massive Gastrointestinal Bleeding. Clin Nucl Med  2003; 28(3):226-7. A

7.1. 3. Top H, Mavi A, Barutcu A, Yilmaz O. Osteocutaneous Flap Prefabrication in Rats.    Plast Reconstr Surg  2004; 113(2):574-84. (Üçüncülük Ödülü) A           

7.1. 4. Aydin A, Durak H, Mavi A, Durak I. 111In Octreotide retention in the orbit of a patient with diabetic retinopathy. Nuklearmedizin 2004;43(2):N21-2.

7.1. 5. Alavi A, Lakhani P, Mavi A, Kung JW, Zhuang H. Imaging With Positron Emission Tomography: A Revolution in Medical Imaging. Radiol Clin North Am 2004; 42(6):983-1001. B   

7.1. 6. El-Haddad G, Alavi A, Mavi A, Bural GG, Zhuang H. Normal Variants in [18F]-  fluorodeoxyglucose PET Imaging. Radiol Clin North Am 2004;42(6):1063-81. B     

7.1. 7. Kumar R, Xiu Y, Potenta S, Mavi A, Zhuang H, Yu JQ, Dhurairaj T, Dadparvar s, Alavi A. 18FDG-PET for Evaluation of the Treatment Response in Patients with Gastrointestinal Tract Lymphomas. J Nucl Med 2004; 45(11):1796-803 A             

7.1. 8. Bural GG, Mavi A, Kumar R, Alavi A. FDG Uptake in Intercostal Muscles Is An Indicator of Severe Respiratory Disease. Clin Nucl Med 2004; 29(12):807-8. A

7.1. 9. Mavi A, Lakhani P, Zhuang H,  Gupta NC, Alavi A. Fluorodeoxyglucose-PET in Characterizing Solitary Pulmonary Nodules, Assessing Pleural Diseases, and the Initial Staging, Restaging, Therapy Planning, and Monitoring Response of Lung Cancer. Radiol Clin North Am  2005; 43(1):1-21.  B

7.1. 10. Kumar R, Mavi A, Bural G, Alavi A. Fluorodeoxyglucose–Positron Emission Tomography in the Management of Malignant Melanoma. Radiol Clin North Am 2005;43(1):23-33. B  

7.1. 11. Takalkar A, Mavi A, Alavi A, Araujo L. PET  in Cardiology. Radiol Clin North Am 2005; 43(1):107-119. B  

7.1. 12. Jadvar H, Alavi A, Mavi A, Shulkin BL. PET  in Pediatric Diseases. Radiol Clin North Am  2005; 43(1):135-52.

7.1. 13. Bural GG, Kumar R, Mavi A, Alavi A. Reflux Esophagitis Secondary to Chemotherapy  Detected By Serial FDG-PET. Clin Nucl Med  2005; 30(3):182-3. A

7.1. 14.Kumar R, Xiu Y, Mavi A, El-Haddad G, Zhuang H, Alavi A. FDG-PET Imaging in Primary Bilateral Adrenal Lymphoma: A Case Report and Review of Literature. Clin Nucl Med  2005; 30(4):222-30. A

7.1. 15. Chamroonrat W, Zhuang H, Houseni M, Mavi A, El-Haddad G, Alavi A. Malignant Lesions Can Mimic Gastric Uptake on FDG-PET. Clin Nucl Med  2006; 31(1):37. A     

7.1. 16.Yu JQ, Zhuang H, Mavi A, Alavi A. Evaluating the Role Fluorodeoxyglucose PET Imaging in the Management of Patient with Sarcoidosis. PET CLINICS  2006;1(2):141-52

7.1. 17. Inceboz T, Mavi A, Kaya GÇ, Korkmaz M, Göktay Y, Yılmaz O, Üner A, Durak H. The ability of 67Ga scintigraphy to detect the lesions of Echinococcus multilocularis infection: Preliminary result. Ann Nucl Med 2006;20(5):345-8.      

7.1. 18. Mavi A, Urhan M, Yu JQ, Zhuang H, Houseni M, Cermik TF, Thiruvenkatasamy D, Czerniecki B, Schnall M, Alavi A. Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes.J Nucl Med  2006;47(9):1440-6.( 2007 Alavi–Mandel   Ödülü) A

7.1. 19. Arslan N, Mavi A, Kalkan S, Aydin A, Ortac R, Buyukgebiz B, Durak H. Findings of hepatobiliary scintigraphy and liver biopsy in Maroteaux-Lamy syndrome presenting as neonatal cholestasis. Pediatr Int  2006;48(5):498-500. 

7.1. 20. Cermik TF, Mavi A, Acıkgöz G,Houseni M, Dadparvar S, Alavi A. FDG PET in Detecting Primary and Recurrent Malignant Salivary Gland Tumors. Clin Nucl Med 2007;32(4):286-91. A

7.1. 21. Alavi A. Mavi A, Basu S, Fischman A. Is PET-CT the only option ? Eur J Nucl Med Mol Imaging 2007;34(6):819-21. A

7.1. 22. Urhan M, Dadparvar S, Mavi A, Houseni M, Chamroonrat W, Alavi A, Mandel SJ. Iodine-123 as a diagnostic imaging agent in differentiated thyroid carcinoma: a comparison with iodine-131 post-treatment scanning and serum thyroglobulin measuremnt, Eur J Nucl Med Mol Imaging 2007; 34(7):1012-17.

7.1. 23. Abramson R, Mavi A, Cermik TF, Basu S, Wehrli N, Houseni M,     Mishra S, Udupa J, Lakhani P, Maidment ADA, Torigian DA, and Alavi A. Structural – Functional Changes in Normal Breast With Regard to Age as Determined by Mammography, Computed Tomography, Magnetic Resonance Imaging, and Positron Emission Tomography. Semin Nucl Med 2007;37(3):146-53. A

7.1. 24. Blebea JS, Houseni M, Torigian DA, Fan C, Mavi A, Zhuge Y, Iwanaga T, Mishra S,Udupa J, Zhuang J, Gopal R, Alavi A. Structural and functional imaging of normal bone marrow and evaluation of its age-related changes. Semin Nucl Med 2007;37(3):185-94. A

7.1. 25. Mavi A, Cermik TF, Urhan M, Puskulcu H, Basu S, Yu JQ, Zhuang H, Czerniecki B, Alavi A. The effects of estrogen, progesterone, and C-erbB-2 receptor states on 18F-FDG uptake of primary breast cancer lesions. J Nucl Med 2007;48(8):1266-72. A

7.1. 26. Basu S, Mavi A, Cermik T, Houseni M, Alavi A. Implications of Standardized Uptake Value Measurements of the Primary Lesions in Proven Cases of Breast Carcinoma with Different Degree of Disease Burden at Diagnosis: Does 2-Deoxy-2-[F-18]fluoro-D: -glucose-Positron Emission Tomography Predict Tumor Biology? Mol Imaging Biol  2008;10(1):62-6. A

7.1. 27. Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, Schnall M, Alavi A. Comparison of triple-negative and estrogen receptor positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer 2008;112(5):995-1000. A     

7.1. 28. Cermik TF, Mavi A, Basu S, Alavi A. Impact of FDG PET on the preoperative staging of newly diagnosed breast cancer. EurJ Nucl Med Mol Imaging. 2008 Mar;35(3):475-83. Epub 2007 Oct 24.

7.1. 29. Urhan M, Mavi A,  Alavi A. Nanni C. Positron Emission Tomography and Thyroid Cancer. PET Clin.  2007;2(3):295-304.

7.1. 30. A Mavi, T Dhuriraj, T Cermik, M Urhan, S Basu, R Kumar, D Torigian, Alavi A. Central Photopenic Lesions On FDG-PET scan In a patient with peripheral T cell lymphoma. Ann Nucl Med. 2008 Aug;22(7):629-33. Epub 2008 Aug 29.       

7.1.31. Houseni M, Chamroonrat W Basu S, Bural G, Mavi A, Kumar R, Alavi A. Usefulness of non attenuation corrected 18F-FDG-PET images for optimal assessment of disease activity in patients with lymphoma. Hell J Nucl Med 2009, Jan-Apr;12(1):5-9.   

7.1. 32. Mavi A, Basu S, Cermik TF, Urhan M.et al. Potential of Dual Time Point FDG-PET Imaging in Differentiating Malignant from Benign Pleural Disease. Mol & Biol. 2009 Sep-Oct;11(5):369-78. Epub 2009 May 27  A

7.1. 33. Benard F, and Mavi A. Receptor Imaging in Patients with Breast Cancer.  PET Clin. 2009;4(4):329-341.

7.1. 34. Basu S, Kumar R, Mavi A, Alavi A. Exploring Tumor Biology with Fluorodeoxyglucose-Positron Emission Tomograpy Imaging in breast Carcinoma.  PET Clin. 2009;4(4):381-389.

7.1. 35. Cermik TF, Mavi A,  Alavi A. Role of [F-18]-2-Deoxy-2-Fluoro-D-Glucose PET and PET/CT in Staging and Follow-Up of Breast Cancer. PET Clin. 2009;4(4):391-404.

7.1. 36. Mavi A, Cermik TF, Urhan M, Puskulcu H, Basu S, Cucchiara AJ, Yu JQ, Alavi A. The effect of age, menopausal state, and breast density on (18)F-FDG uptake in normal glandular breast tissue. J Nucl Med. 2010 ;51(3):347-52. ( 2010 Alavi-Mandel ödülü) A  

 

7. 2. Uluslararası diğer hakemli dergilerde yayımlanan     

        Makaleler:   10 adet  (7.1’de yazıldı)

 

7. 3. Uluslararası bilimsel kongrelerde sunulan ve bildiri kitabında

     (Proceedings) basılan bildiriler. 16 Uluslararası kongrede toplam : 72

  

  • 28’i  Sözel Sunum  (UA-S)
  • 44’i  Poster  (UA-P)

 

7.3. 1. Kumar R, Bozkurt MF, Xiu Y, Kung JW, Yu JQ, Takalkar A, Dadparvar S, Bural G, Mavi A, Wintering N, Alavi A.  FDG-PET in Assessing Adrenal Masses Detected By CT/MRI in Patients With Known Malignancies. 51st Annual Meeting of Society of Nuclear Medicine, June 19-23, 2004, Philadelphia, PA. ABD. J Nucl Med. 2004;45(5) Abstract Book Supplement: P 35.  UA-S

7.3. 2. Mavi A, Bural G, Kumar R, El-Haddad G, Cheng E, Wintering N, Alavi A.  Metabolic Consequence of Age on Head and Neck Structures As Determined By FDG-PET Imaging. 51st Annual Meeting of Society of Nuclear Medicine, June 19-23, 2004, Philadelphia, PA. ABD. J Nucl Med. 2004;45(5) Abstract Book Supplement: 135 P. UA-S

7.3. 3. Bural G, Mavi A, Kumar R, Chiang S, El-Haddad G, Cheng E, Wintering NA, Alavi A.  Standardized Uptake Values in the Cervical Spinal Cord: Change With Age and Gender As Determined By FDG-PET Imaging. 51st Annual Meeting of Society of Nuclear Medicine, June 19-23, 2004, Philadelphia, PA. ABD. J Nucl Med. 2004;45(5) Abstract Book Supplement: 281 P.  UA-P

7.3. 4.  El-Haddad G, Bozkurt MF, Kumar R, Bural G, Xiu Y, Mavi A, Zhuang HM, Alavi A.  The Changes of Standardized Uptake Values in Bowel With Age. 51st Annual Meeting of Society of Nuclear Medicine, June 19-23, 2004, Philadelphia, PA. ABD. J Nucl Med. 2004;45(5) Abstract Book Supplement: 293 P. UA-P

7.3. 5. Bural G, Mavi A, Kumar R, El-Haddad G, Cheng E, Wintering N, Alavi A.  Metabolic Consequence of Age on Thoracic Structures As Determined By FDG-PET Imaging.  51st Annual Meeting of Society of Nuclear Medicine, June 19-23, 2004, Philadelphia, PA. ABD. J Nucl Med. 2004;45(5) Abstract Book Supplement: 310 P. UA-P

7.3. 6. Bural GG, Mavi A, Kumar R,  El-Haddad G, Srinivas S, Alavi A. FDG-PET Imaging As A Potential Modality For Detecting Atherosclerotic Lesions in the Major Arteries. 9th Annual Scientific Session of American Society of Nuclear Cardiology, Sept.30-Oct.3, New York, New York, USA. Journal of Nuclear Cardiology  2004;11(4):S23. UA-P

7.3. 7. Bural GG, El-Haddad G, Mavi A, Alavi A, Araujo L. The Effect of Glucose Load on Both Cardiac and Skeletal Muscle FDG Uptake. 9th Annual Scientific Session, of American Society of Nuclear Cardiology, Sept.30-Oct.3, 2004, New York,  New York, USA. Journal of Nuclear Cardiology 2004;11(4):S24. UA-P

7.3. 8.  Kumar R,  Zhuang H, Potenta S, Yu J, Mavi A, Bural G, Alavi A. Positron Emission Tomography for Staging Gastric Cancer.”90th Scientific Assembly and Annual Meeting Program of Radiological Society of North America (RSNA)”, Nov.28-Dec.3, 2004, Chicago, USA, RSNA Scientific Assembly and Annual Meeting Program 2004:P701. UA-S

7.3. 9.  Mavi A, Cheng E, Kumar R, Posteraro A, El-Haddad G, Srinivas S, Alavi A, Zhuang H. The Effect of Anatomical Region and the Size of the Lesions on Spatial Misregistration in PET-CT Images. Annual Conference of the Academy of Molecular Imaging, 18-23 March  2005, Orlando, Florida, USA. Molecular Imaging and Biology 2005; 7(2):171. UA-P

7.3. 10. Mavi A, Urhan M, Dhurairaj T, Houseni M, Kumar R, Yu JQ, Zhuang H, Orel S, Schnall M, Alavi A. Dual Time Point Imaging: An Effective Method for Improving the Detection Rate of 18FDG PET Imaging in Primary Breast Cancer“,31th Annual Meeting of the American College of Nuclear Physicians, Jan 15-19, 2005, San Diego, CA  USA, Abstract Book:p 26. “”BEST ORAL PRESENTATION AWARD” UA-S

7.3. 11. El-Haddad G, Mavi A, Houseni M, Alavi A, Zhuang H. Efficacy of FDG-PET in Detecting Metastases From Renal Cell and Bladder Carcinomas. 52nd Annual Meeting of Society of Nuclear Medicine, Jun.18-23, Toronto, Canada, J Nucl. Med. 2005;46(supp 2): 105 P. UA-S  

7.3. 12. Lakhani P, Maidment AD, Mavi A, Urhan M, Alavi A. Correlation Between Volumetric Breast Density From Digital Mammography With FDG-PET Uptake in Normal Breasts. 52nd Annual Meeting of Society of Nuclear Medicine, Jun.18-23, 2005, Toronto, Canada, J Nucl Med. 2005;46(supp 2):  235 P. UA-P

7.3. 13. El-Haddad G, Zhuang H, Yu JQ, Shrikanthan S, Mavi A, Alavi A. Maximal Suv Is Superior to Mean SUV in Differentiating Malignant From Inflammatory Disease By Utilizing Dual Time FDG-PET Imaging. 52nd Annual Meeting of Society of Nuclear Medicine, Jun.18-23,  2005, Toronto, Canada, J Nucl Med. 2005;46(supp 2): 239 P. UA-P

7.3. 14. Kumar R, Xiu Y, Zhuang H, El-Haddad G, Mavi A, Alavi A. F-18-Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) in Evaluation of Primary Cutaneous Lymphoma. 52nd Annual Meeting of Society of Nuclear Medicine, Jun.18-23, 2005, Toronto, Canada, J Nucl Med.2005;46(supp 2): 379 P. UA-P

7.3. 15. Mavi A, Liu FM, Zhuang H, Dhurairaj T, Houseni M, Dadparvar S, Alavi A. Prognostic Value of FDG PET in Malignant Mesothelioma. 52nd Annual Meeting of Society of Nuclear Medicine, Jun.18-23, 2005, Toronto, Canada, J Nucl Med.2005;46(supp 2): 426 P. UA-P

7.3. 16. Kumar R, Xiu Y, Zhuang H, Bural G, Mavi A, Alavi A. Usefulness of FDG-PET in Detection of Local and Distant Recurrent Cervical cancer in Symptomatic Women. 52nd Annual Meeting of Society of Nuclear Medicine, Jun.18-23, 2005, Toronto, Canada, J Nucl Med. 2005;46(supp 2): 438 P. UA-P

7.3. 17. Urhan M, Mavi A, Houseni M, Dadparvar S, Alavi A, Mandel S. The Role of 18FDG PET in Differentiated Thyroid Carcinoma Patients with a Clinical Suspicion of Non-Iodine Avid Metastases. Annual Congress of European Association of Nuclear Medicine, 15-19 October 2005, İstanbul, Turkey, Eur J Nucl Med Mol Imaging. 2005; 32(supp 1):28 P UA-S

7.3. 18. Urhan M, Shrikanthan S, Mavi A, Houseni M, Dadparvar S, Alavi A, Mandel S. The Complementary Role of FDG-PET to Other Diagnostic Imaging Techniques in the Follow-up of Well-Differentiated Thyroid Carcinoma. Annual Congress of European Association of Nuclear Medicine, 15-19 October 2005, İstanbul,  Turkey,  Eur J Nucl Med Mol Imaging. 2005; 32(supp 1): 28 P. UA-S

7.3. 19. Mavi A, Urhan M, Zhuang H, Yu JQ, Houseni M, Czerniecki BJ, Schnall MD, Alavi A. The Effect of Receptor Status on FDG Uptake and SUV Change over Time in Patients with Newly Diagnosed Breast Cancer.  Annual Congress of European Association of Nuclear Medicine, 15-19 October 2005, İstanbul,  Turkey,  Eur J Nucl Med Mol Imaging. 2005; 32(supp 1): 71 P UA-S

7.3. 20. Mavi A, Urhan M, Zhuang H, Yu JQ, Czerniecki BJ, Houseni M, Schnall MD, Newberg A, Alavi A. The Role of FDG-PET Imaging in Preoperative Axillary Staging of Breast Cancer Compared With Sentinal Lymph Node Biopsy and Axillary Dissection.   Annual Congress of European Association of Nuclear Medicine, 15-19 October, 2005, İstanbul,  Turkey,  Eur J Nucl Med Mol Imaging. 2005; 32(supp 1):119 P. UA-S

7.3. 21. Mavi A, Dhurairaj T, Houseni M, Urhan M, Dadparvar S, El-Haddad G, Zhuang H, Alavi A. Dual Time Point Imaging Is An Effective Method That Can Differentiate Malignant From Benign Pleural Disease.    Annual Congress of European Association of Nuclear Medicine, 15-19 Oct. 2005, İstanbul,  Turkey,  Eur J Nucl Med Mol Imaging 2005;32(supp 1): 144 P. UA-P

7.3. 22. Mavi A, Dhurairaj T, Houseni M, Urhan M, Chamroonrat W, Dadparvar S, Zhuang H, Alavi A. The Role of Metabolic FDG-PET Imaging in the Diagnosis and Management of Malignant Mesothelioma. Annual Congress of European Association of Nuclear Medicine, 15-19 Oct. 2005, İstanbul,  Turkey,  Eur J Nucl Med Mol Imaging 2005; 32(supp 1): 145 P. UA-P

7.3. 23. Houseni M, Chamroonrat W, Bural GG, Urhan M, Mavi A, Zhuang H, Alavi A. Distinct Prevalence of Recurrent Disease in Patients with Head and Neck Cancer Following Different Therapy Regime Demonstrated by FDG-PET.   Annual Congress of European Association of Nuclear Medicine, 15-19 Oct. 2005,İstanbul,Turkey,Eur J Nucl Med Mol Imaging 2005;32(supp 1):149 P. UA-P

7.3. 24. Houseni M, Chamroonrat W, Mavi A, Bural GG, Urhan M, Dadparvar S, Zhuang H,  Alavi A. Non Attenuation Corrected (In Addition to Corrected) FDG-PET Images are Essential for Optimal Assessment of Patients with Lymphoma.   Annual Congress of European Association of Nuclear Medicine, 15-19 Oct. 2005, İstanbul,   Turkey,  Eur J Nucl Med Mol Imaging 2005; 32(supp 1): 155 P. UA-P

7.3. 25. Urhan M, Mavi A, Houseni M, Alavi A, Mandel S. The Role of 18FDG PET in Patients With Recurrent Thyroid Medullary Carcinoma.   Annual Congress of European Association of Nuclear Medicine, 15-19 Oct. 2005, İstanbul,   Turkey,  Eur J Nucl Med Mol Imaging 2005; 32(supp 1): 158 P. UA-P

7.3. 26. Mavi A, Urhan M, Zhuang H, Yu JQ, Houseni M, Czerniecki BJ, Schnall MD,  Alavi A. The Effect of Age, Density and Menopausal Status on FDG Uptake in Normal Breast Glandular Tissue. 2005. Annual Congress of European Association of Nuclear Medicine, 15-19 Oct. 2005, İstanbul,  Turkey,  Eur J Nucl Med Mol Imaging 2005; 32(supp 1): 158 P. UA-P

7.3. 27. Houseni M, Mavi A, Chamroonrat W, Bural GG, Urhan M, El-Haddad G,Zhuang H, Alavi A. PET/CT: Evaluation of The Correction For Attenuation.   Annual Congress of European Association of Nuclear Medicine, 15-19 Oct. 2005, İstanbul,  Turkey,  Eur J Nucl Med Mol Imaging 2005; 32( supp 1):  258 P. UA-P

7.3. 28. Urhan M,  Mavi A,  Houseni M, Chamroonrat W,  Zhuang H,   Alavi A, and Mandel S. 123I  as a dıagnostıc ımagıng agent in dıfferentiated thyroid carcinoma : Comparison with 131I  post-treatment scanning. “19th Annual Northeast Regional Scientific Meeting Greater New York and New England Chapters of the Society of Nuclear Medicine”, Oct 28-30, 2005. Newport, Rhode Island, USA. Clin Nucl Med.2006; 31(2):119. UA-P

7.3. 29. Urhan M,  Mavi A,  Houseni M,   Alavi A, and Mandel S. The administration of recombinant human TSH (RHTSH) before 123I  diagnostic imaging and high dose treatment of dıfferentiated thyroid carcinoma. “19th Annual Northeast Regional Scientific Meeting Greater New York and New England Chapters of the Society of Nuclear Medicine”, Oct 28-30, 2005. Newport, Rhode Island, USA. Clin Nucl Med. 2006; 31(2):119. UA-P

7.3. 30. Mavi A, Urhan M,    Zhuang H,   Yu J,  Thiruvenkatasarny D, Houseni M, Alavi A. “The role of histopathology (invasive versus noninvasive) on SUV uptake in primary breast cancer on dual time PET imaging.” 91th Scientific Assembly and Annual Meeting Program of  Radiological Society of North America (RSNA), Nov.27-Dec.2, 2005, Chicago, USA, RSNA Scientific Assembly and Annual Meeting Program : P682  (2005 TRAINEE RESEARCH PRIZE) UA-P

7.3. 31. Mavi A, Cermik T.F,  Houseni M, Bathaii M, Dadparvar S, Zhuang H, Alavi A. Impact of the FDG-PET in the management of patients with pancreatic cancer. 53rd Annual Meeting of Society of Nuclear Medicine, June 3-7,2006, San Diego,  CA, USA. J Nucl. Med. 2006; 47(Supp 1):42P. UA-S

7.3. 32. Acikgoz  G,  Houseni M, Alkhawaldeh K, Cermik TF, Dadparvar S, Mavi A, Alavi A. Detection of extramedullary and extranodal involvement of leukemia with FDG-PET. 53rd Annual Meeting of Society of Nuclear Medicine, June 3-7, 2006, San Diego, CA, USA. J Nucl. Med. 2006; 47(Supp 1):51 P. UA-S

7.3. 33. Fan C, Pampaloni MH, Houseni M, Chamroonrat W, Bathaii M, Mavi A, Bural G, Alkhawaldeh K, Torigian DA, Alavi A. A primary study of 18FDG-PET imaging in human red marrow  metabolism with advancing age. 53rd Annual Meeting of Society of Nuclear Medicine, June 3-7, 2006, San Diego,  CA, USA. J Nucl. Med. 2006; 47(Supp 1): 89P. UA-S

7.3. 34.  Cermik TF, Mavi A, Açıkgöz G,  Dadparvar S,  Zhuang H,   Alavi A. FDG-PET  in detecting the primary and recurrent salivary gland cancer. 53rd Annual Meeting of Society of Nuclear Medicine, June 3-7, 2006, San Diego,  CA, USA. J Nucl. Med. 2006; 47(Supp 1): 111 P. UA-S

7.3. 35.  Bathaii M, Bural G, Alkhawaldeh K, Fan C,   Mavi A,   Alavi A. Role of FDG-PET in detecting residual/recurrent brain tumor in post-operative pediatric patients with inconclusive MRI. 53rd Annual Meeting of Society of Nuclear Medicine, June 3-7, 2006 San Diego,  CA, USA. J Nucl. Med. 2006; 47(Supp 1): 145P. UA-S

7.3. 36. Houseni M,  Chamroonrat W,  Bural G, El-Haddad G,  Acikgoz  G, Yang H, Alkhawaldeh K,  Mavi A,  Alavi A. Metabolic activities of metastatic lesions to the liver as measured by FDG-PET vary considerably depending on the origin of the primary malignancy. 53rd Annual Meeting of Society of Nuclear Medicine, June 3-7, 2006 San Diego,     CA, USA. J Nucl. Med. 2006; 47(Supp 1): 222P. UA-S

7.3. 37. Houseni M,  Chamroonrat W,  Bural G, Yang H, El-Haddad G,  Acikgoz  G, Alkhawaldeh K, Mavi A, Urhan M, Alavi A. Promising role of dual time FDG-PET imaging in assessing focal and diffuse bone marrow disorders. 53rd Annual Meeting of Society of Nuclear Medicine, June 3-7, 2006, San Diego,  CA, USA. J Nucl. Med. 2006; 47(Supp 1): 227P UA-S

7.3. 38. Cermik TF, Mavi A, Zhuang H, Newberg A, Alavi A. The value of partial volume correction in the detection of the primary breast cancer. 53rd Annual Meeting of Society of Nuclear Medicine, June 3-7, 2006 San Diego, CA, USA. J Nucl Med. 2006;47,(supp 1): 388P. UA-P

7.3. 39.  Mavi A, Cermik TF, Zhuang H, Newberg A, Alavi A. The relationship between the degree of FDG uptake on PET studies and the presence of metastasis at the time of diagnosis of the primary breast cancer. 53rd Annual Meeting of Society of Nuclear Medicine, June 3-7, 2006 San Diego, CA, USA. J Nucl Med. 2006; 47(supp 1): 436P. UA-P

7.3. 40. Mavi A, Cermik TF, Urhan M, Yu JQ, Zhuang H, Newberg A, Alavi A. The effect of breast density on FDG uptake and ıts change over time in normal breast tissue. 53rd Annual Meeting of Society of Nuclear Medicine, June 3-7, 2006 San Diego,  CA, USA. J Nucl Med. 2006; 47(supp 1): 436P. UA-P 

7.3. 41. Cermik TF, Mavi A,  Houseni M, Açıkgöz  G, Zhuang H, Dadparvar S,  Alavi A. FDG-PET in the assessment of recurrens, metastases and therapy response in patents with testicular cancer. 53rd Annual Meeting of Society of Nuclear Medicine, June 3-7, 2006 San Diego, CA, USA. J Nucl Med. 2006;47(supp 1): 459P. UA-P

7.3. 42. Cermik TF, Mavi A,  Açıkgöz  G, Houseni M, Dadparvar S, Zhuang H, Alavi A. Evolving role of FDG-PET imaging in the management of patients with gall bladder cancer and cholangiocarcinoma. 53rd Annual Meeting of Society of Nuclear Medicine, June 3-7, 2006 San Diego, CA, USA. J Nucl Med. 2006;47(supp 1): 463P. UA-P

7.3. 43. Cermik TF, Mavi A, Zhuang H, Newberg A, Alavi A. The role of whole body FDG PET in detecting locoregional and distant metastatic lesions in patients with newly diagnosed breast cancer. Annual Congress of the European Association of Nuclear Medicine, 1-3 Oct. 2006, Athens, Greece, Eur J Nucl Med Mol Imaging. 2006; 33(supp 2): S166. UA-S

7.3. 44. Mavi A, Cermik TF, Urhan M, Zhuang H, Alavi A.